Physician profile
Raymond Wechman
NPI 1063497113
$1,257.22
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $473 · 2021: $465 · 2022: $189.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $264.75 | 2020-2022 | |
| Amgen INC. | $152.27 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.81 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $95.57 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $84.34 | 2020 | |
| Lilly USA, LLC | $74.55 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.44 | 2020-2021 | |
| Pfizer INC. | $66.15 | 2019-2022 | |
| Novo Nordisk INC | $53.75 | 2021-2022 | |
| Abbvie INC. | $46.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $45.26 | 2020-2021 | |
| Astellas Pharma US INC | $38.95 | 2019 | |
| Amarin Pharma, INC. | $35.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $33.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.79 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15.34 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Wechman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.